文献速递血栓与止血

儿童难治性慢性免疫性血小板减少症:识别、患者特征与结局

Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome.
PubMed 文献 · Am J Hematol · 2024-04-23

在886例慢性免疫性血小板减少症(cITP)患儿中比较7种难治性cITP(r-cITP)定义,5种儿科定义识别出4%-20%的重叠人群且特征相似(免疫病理表现及系统性红斑狼疮比例较高)。按CEREVANCE定义(≥3种二线治疗)共79例r-cITP,年新发率1.15%,2年持续完全缓解累积发生率为9%,脾切除术与持续完全缓解累积发生率较高相关(HR 5.43)。

要点

  • 5种儿科r-cITP定义识别出4%-20%的重叠人群,特征相似。
  • 按CEREVANCE定义r-cITP年新发率为1.15%,随访期间未出现平台期。
  • r-cITP诊断后2年持续完全缓解累积发生率为9%,脾切除术与较高累积发生率相关(HR 5.43)。

核心结论

  • cITP患儿可在随访任意时间点被诊断为r-cITP,且免疫病理表现和系统性红斑狼疮风险增加。
  • 二线治疗似乎可有效预防5级出血。
  • 作者认为可考虑脾切除术以实现持续完全缓解。

研究设计与样本

  • 比较7种r-cITP定义(含5种儿科定义)在886例cITP患者中的表现,中位随访5.3年(范围1.0-29.3年)。
  • 基于CEREVANCE定义(≥3种二线治疗)识别79例r-cITP患者,中位随访3.1年(范围0-18.2年)。

主要发现

  • 5种儿科定义识别出大小重叠的人群(4%-20%),其特征相似(免疫病理表现和系统性红斑狼疮比例较高)。
  • r-cITP年新发率为1.15%新患者/年,且随时间未出现平台期。
  • 多因素分析中,年龄较大与r-cITP相关。
  • 1例患者(1%)在符合r-cITP标准后且未接受二线治疗期间发生两次5级出血事件。
  • r-cITP诊断后2年持续完全缓解累积发生率为9%;脾切除术与较高的持续完全缓解累积发生率相关(HR 5.43,95%CI 1.48-19.84,p=7.8×10⁻⁴)。

临床怎么用

  • 作者认为二线治疗似乎可有效预防5级出血。
  • 作者认为可考虑脾切除术以实现持续完全缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Refractory chronic immune thrombocytopenia (r-cITP) is one of the most challenging situations in chronic immune thrombocytopenia (cITP). Pediatric r-cITP is inconsistently defined in literature, contributing to the scarcity of data. Moreover, no evidence is available to guide the choice of treatment. We compared seven definitions of r-cITP including five pediatric definitions in 886 patients with cITP (median [min-max] follow-up 5.3 [1.0-29.3] years). The pediatric definitions identified overlapping groups of various sizes (4%-20%) but with similar characteristics (higher proportion of immunopathological manifestations [IM] and systemic lupus erythematosus [SLE]), suggesting that they adequately captured the population of interest. Based on the 79 patients with r-cITP (median follow-up 3.1 [0-18.2] years) according to the CEREVANCE definition (≥3 second-line treatments), we showed that r-cITP occurred at a rate of 1.15% new patients per year and did not plateau over time. In multivariate analysis, older age was associated with r-cITP. One patient (1%) experienced two grade five bleeding events after meeting r-cITP criteria and while not receiving second-line treatment. The cumulative incidence of continuous complete remission (CCR) at 2 years after r-cITP diagnosis was 9%. In this analysis, splenectomy was associated with a higher cumulative incidence of CCR (hazard ratio: 5.43, 95% confidence interval: 1.48-19.84, p = 7.8 × 10-4). In sum, children with cITP may be diagnosed with r-cITP at any time point of the follow-up and are at increased risk of IM and SLE. Second-line treatments seem to be effective for preventing grade 5 bleeding. Splenectomy may be considered to achieve CCR.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Pincez T, Fernandes H, Fahd M, et al. Pediatric refractory chronic immune thrombocytopenia: Identification, patients' characteristics, and outcome. Am J Hematol. 2024. PMID: 38651646. doi:10.1002/ajh.27337

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。